Systematically Engineered Nanodrugs using by ...

Systematically Engineered Nanodrugs using by Formulation by Design (Fbd) Approach

Author Name : Rakesh Paul, Somnath Sahoo, Sumant Saini

DOI: https://doi.org/10.56025/IJARESM.2023.117237

ABSTRACT

Nanomedicine is the use of nanoscale technology to the safe, effective, and patient-acceptable management of diseases. This integrative study has recently demonstrated unequalled promise for revolutionising the therapeutic approach for diagnosing, preventing, treating, and curing several diseases, including cancer. Recent medical research has concentrated on nanomedicine due to the uniqueness of the many nanoconstructs employed in it. By adjusting the biopharmaceutic and pharmacokinetic characteristics of innovative drug candidates, nanodrug systems may be a possible technique to get the drug attributes. Hydrophilic polymers, liposomes, micelles, protein nanoparticles, inorganic nanoparticles, antibody-drug conjugates, and nanocrystals are among the several types of FDA-approved synthetic nanomedicines. We have discussed here the Change from OVAT to a thorough DoE-based quality-by-design philosophy (QbD). The five-step DoE optimization technique subject provides thorough information on numerous DoE elements. Pharmaceutical Quality by Design (QbD) is a systematic approach to product development that begins with predetermined goals and emphasises knowledge and control of the product and process based on trustworthy science and quality risk management. We also discussed QbD approach to product development, a candidate identifies characteristics that, from the viewpoint of the patient, are critical to quality, turns them into the pharma product's critical quality attributes (CQAs), and sets up the relationship among manufacturing variables and CQAs to reliably deliver a drug product with these CQAs to the patient. The adoption of these methodical FbD paradigms, along with technological advancements, rising incidence of acute and chronic diseases, global acceptance of nanopharmaceutical products, growing geriatric population, and a notable increase in R&D activities by corporate as well as governmental organisations, are some of important components likely to encourage the development of nanomedicines all across the world in the near future.

Keywords: Formulation by Design (FbD), Quality by Design (QbD), Nanodrugs, Pharmaceuticals, Biogenic nanostructured.